Biopharmaceutical - Targeted Protein Degradation (TPD)
Strategic Profile
The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with immunological conditions.
Cyborg Score Rationale
Kymera has a validated platform with phase 2b trials underway, strong analyst coverage with "Strong Buy" consensus, and a strategic partnership with Sanofi. However, the company faces typical biotech risks with losses exceeding revenues and significant cash burn, though recent positive clinical data supports growth trajectory.
Top Insights
Kymera reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis.
KT-621 BROADEN2 Phase 2b trial in AD initiated, with KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26.
One of Kymera Therapeutics's 36 competitors is Foghorn Therapeutics, a formerly VC-backed company based in Cambridge, MA.
According to 24 analysts, the average rating for KYMR stock is "Strong Buy" with a 12-month stock price target of $105.35, representing 48.55% upside from latest price.
Named Competitors
Targeted Protein Degradation — PROTAC-based protein degradation therapeutics
Protein Degradation Platform — E3 ligase modulator-based degraders
Targeted Protein Degradation — Targeted protein degradation for undruggable targets
Recent Developments
(December 2025) Positive Phase 1b data for KT-621 in atopic dermatitis reported